Clinicopathological characteristics of patients with telomere length

AuthorYearTumor gradeTumor stageMenopausal statusLNMHER2ERPR
31 and 2III and IVI and IIPostmenopausalPremenopausal(+)(–)(+)(–)(+)(–)(+)(–)
Duggan et al. [17]2014--------------
Fordyce et al. [18]2006--9 (S)/5 (L)26 (S)/19 (L)--27 (S)/12 (L)8 (S)/12 (L)------
Gay-Bellile et al. [19]2016--------------
Heaphy et al. [20]200790 (S)/14 (L)204 (S)/43 (L)5 (S)/0 (L)428 (S)/84 (L)299 (S)/59 (L)131 (S)/25 (L)--189 (S)/35 (L)251 (S)/49 (L)373 (S)/71 (L)67 (S)/15 (L)297 (S)/62 (L)144 (S)/23 (L)
Lu et al. [21]2011144 (S)/23 (L)93 (S)/100 (L)18 (S)/16 (L)149 (S)/146 (L)--74 (S)/83 (L)94 (S)/79 (L)--109 (S)/107 (L)59 (S)/56 (L)82 (S)/91 (L)86 (S)/71 (L)
Shen et al. [23]2012----315 (S)/359 (L)183 (S)/145 (L)--325 (S)/344 (L)185 (S)/172 (L)254 (S)/253 (L)72 (S)/86 (L)254 (S)/253 (L)72 (S)/86 (L)
Simpson et al. [22]2015--------------
Svenson et al. [24]2008--------------
Vodenkova et al. [25]2020--------------

S: short telomere length; L: long telomere length; LNM: lymph node metastasis; HER2: human epidermal growth factor receptor 2; ER: estrogen receptor; PR: progesterone receptor